AGYTF (Allergy Therapeutics) Total Assets: $95.05 Mil (As of Dec. 2025)


AGYTF Allergy Therapeutics PLC AGYTF
29 GF Score
Price $0.13
GF Value $0.03
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Allergy Therapeutics Total Assets?

Allergy Therapeutics AGYTF 29 Total Assets is $95.05 Mil as of Dec. 2025. GuruFocus rates AGYTF with a GF Score™ of 29/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Allergy Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $95.05 Mil.

During the past 12 months, Allergy Therapeutics's average Total Assets Growth Rate was 18.80% per year. During the past 3 years, the average Total Assets Growth Rate was 1.40% per year. During the past 5 years, the average Total Assets Growth Rate was 2.60% per year. During the past 10 years, the average Total Assets Growth Rate was 6.80% per year.

During the past 13 years, Allergy Therapeutics's highest 3-Year average Total Assets Growth Rate was 23.20%. The lowest was -3.80%. And the median was 7.30%.

Total Assets is connected with ROA %. Allergy Therapeutics's annualized ROA % for the quarter that ended in Dec. 2025 was -57.13%. Total Assets is also linked to Revenue through Asset Turnover. Allergy Therapeutics's Asset Turnover for the quarter that ended in Dec. 2025 was 0.52.

Allergy Therapeutics  (OTCPK:AGYTF) Total Assets Explanation

Total Assets is connected with ROA %.

Allergy Therapeutics's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-53.328/( (91.646+95.052)/ 2 )
=-53.328/93.349
=-57.13 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Allergy Therapeutics's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=48.568/( (91.646+95.052)/ 2 )
=48.568/93.349
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Allergy Therapeutics Total Assets Related Terms

Allergy Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Allergy Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics Total Assets Chart

Allergy Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 123.55 89.84 86.40 84.49 91.65

Allergy Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.44 84.49 92.25 91.65 95.05
AGYTF
29GF Score
Allergy Therapeutics PLC AGYTF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allergy Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Allergy Therapeutics's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (A: Jun. 2025 )+Total Liabilities (A: Jun. 2025 )
=-38.254+129.9
=91.65

Allergy Therapeutics's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=5.688+89.364
=95.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $95.05 Mil mean?
Allergy Therapeutics (AGYTF) has a Total Assets of $95.05 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Allergy Therapeutics and its competitors.
Is Allergy Therapeutics' Total Assets too high?
Allergy Therapeutics' current Total Assets is $95.05 Mil. Overall, Allergy Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Allergy Therapeutics' Total Assets compare to ZTS and UTHR?
Allergy Therapeutics' Total Assets of $95.05 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Allergy Therapeutics and its competitors. Allergy Therapeutics's current Total Assets is $95.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (AGYTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $0.13 — trading 333.3% above its estimated fair value. The current Total Assets is $95.05 Mil. Allergy Therapeutics' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Allergy Therapeutics (AGYTF), the current Total Assets is $95.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Allergy Therapeutics (AGYTF) Overvalued in 2026?

Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued. The current stock price of $0.13 is trading 333.3% above its estimated GF Value™ of $0.03. GuruFocus considers Allergy Therapeutics to be Significantly Overvalued.

Key valuation signals for AGYTF:

  • Total Assets: $95.05 Mil
  • GF Value™: $0.03 vs. price of $0.13 (333.3% above fair value)
  • GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the AGYTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Allergy Therapeutics Business Description

Other Exchanges AGY:UKHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
29GF Score

Get the complete analysis for AGYTF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$0.03
GF Value